auracil (12) by using standard deoxyribosidation methodology. Compound 7 was prepared from 5-(3-furyl)-6-azauracil (33) via a ribosidation/deoxygenation sequence. An attempt to prepare the corresponding 5-(2,2-difluorovinyl) analogue afforded instead a mixture of the 5-[(2,2-difluoro-2-methoxy)ethyl] and 5-(2,2,2-trifluoroethyl) derivatives 29 and 30. Compounds 2-7, 29, and 30 were tested for in vitro
合成了以下5-(2-取代的
乙烯基)-
6-氮杂-2'-脱氧尿苷:(E)-5-(2-
溴乙烯基)(2)(6-氮杂-BVDU),5-(2-
溴-2-
氟乙烯基)(E和Z异构体的混合物)(3),(E)-5-(2-
氯乙烯基)(4),(E)-5- [2-(甲
硫基)
乙烯基](5) ,5-(2,2-二
溴乙烯基)(6)和5-(3-
呋喃基)(7)。2-6的合成利用了对5-甲酰基-1-(2'-脱氧-3',5'-二-Op-
甲苯甲酰基-β-D-赤型戊
呋喃糖基)-6-氮杂尿
嘧啶的Wittig型反应(16 )。还使用标准脱氧
核糖基化方法由(E)-5-(2-
溴乙烯基)-6-氮杂尿
嘧啶(12)合成6-Aza-BVDU(及其α-端基异构体)。化合物7由5-(3-
呋喃基)-6-氮杂尿
嘧啶(33)经
核糖化/脱氧序列制备。尝试制备相应的5-(2,2-二
氟乙烯基)类似物,相反提供了5-[((2,2-二
氟-2-甲氧基)乙基]和5-(2,2,